Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

NCT05835180 is registered in ClinicalTrials.gov with Sagimet Biosciences Inc. as lead sponsor.

NCT NCT05835180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05835180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Lead sponsor
Sagimet Biosciences Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 1, 2023
Completion date
December 18, 2023
Enrollment
48 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, hepatic impairment, non-alcoholic steatohepatitis